Remote arm treatment to protect the heart during chemo
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies whether a simple “remote conditioning” treatment on the arm can help protect the heart while you receive chemotherapy that includes anthracyclines. If you’re at higher risk for heart damage from chemo, this may reduce risk and help monitor heart function over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have NHL, HL, or breast cancer.
- Your planned chemotherapy includes anthracyclines totaling at least 240 mg per square meter (mg/m²).
- Your heart ultrasound before starting chemo shows an ejection fraction above 40%.
- You have at least one heart-damage risk factor (such as prior heart artery disease, high blood pressure, kidney disease, smoking history, obesity, diabetes, or others listed by the study).
- You cannot have certain exclusions, such as a prior heart failure diagnosis or permanent atrial fibrillation.
- You must be able to do follow-up visits and give consent; also you should not have severe claustrophobia or certain implanted devices that make MRI unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a heart-protecting drug (dexrazoxane) can prevent heart damage in people getting chemotherapy for certain types of large B-cell lymphoma. It is for patients who already have heart risk factors or a history of heart failure.
This early-phase study tests a “neuromodulation” device (stimulating nerves that may affect the heart and blood vessels) to help lower cardiovascular risks after certain cancer chemotherapy. It may be most relevant if you recently had an anthracycline-based treatment and also have other heart-risk factors.
This trial tests if taking rosuvastatin (a cholesterol-lowering pill) can help prevent heart damage from anthracycline chemotherapy in women with breast cancer. If you are about to start this type of chemo and have not used statins before, you may qualify.
This study tests a method to predict and warn about heart damage from a common type of breast cancer chemotherapy. If you have HER2-positive breast cancer and will receive anthracycline drugs, this trial may help monitor your heart health.
This study uses heart imaging scans and blood tests to check if a common cancer drug (anthracycline) is affecting your heart during treatment. Early detection might help doctors protect your heart health.
This trial checks how well the heart handles anthracycline chemotherapy in breast cancer patients. It helps doctors find early signs of heart side effects so they can keep you safe during treatment.
Hear when a new Anthracycline-induced Cardiac Toxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.